Development of amphotericin B loaded polymersomes based on (PEG)3-PLA co-polymers: Factors affecting size and in vitro evaluation

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 5, 2010, Pages 456-465

  Jain, Jay Prakash ^a   Kumar, Neeraj ^a  

^a Department of Pharmaceutics   (India)

Author keywords

Amphotericin B; Branched (PEG)3 PLA co polymer; Drug delivery; Drug localization; Polymersomes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; COPOLYMER; DEOXYCHOLATE SODIUM; FLUORESCEIN ISOTHIOCYANATE; MACROGOL; POLYLACTIC ACID; POLYMERSOME; SOLVENT; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; DRUG CARRIER; EMULSION; EXCIPIENT; LACTIC ACID; MICROSPHERE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; SURFACTANT;

ARTICLE; CIRCULAR DICHROISM; CONFOCAL LASER MICROSCOPY; DRUG FORMULATION; DRUG RELEASE; HEMOLYSIS; IN VITRO STUDY; INJECTION; PARTICLE SIZE; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY; VISCOSITY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EMULSION; MALE; NANOTECHNOLOGY; PHARMACEUTICS; RAT;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EMULSIONS; EXCIPIENTS; FLUORESCEIN-5-ISOTHIOCYANATE; HEMOLYSIS; LACTIC ACID; MALE; MICROSPHERES; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; RATS; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953914712     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.05.005     Document Type: Article

References (45)

1. Adams M.L., Kwon G.S. Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N-hexyl--aspartamide)-acyl conjugate micelles: effects of acyl chain length. J. Control. Release 2003, 87:23-32.
2. Anton N., Benoit J.-P., Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J. Control. Release 2008, 128:185-199.
3. Bala I., Hariharan S., Kumar M.N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:387-422.
4. Behrend O., Ax K., Schubert H. Influence of continuous phase viscosity on emulsification by ultrasound. Ultrason. Sonochem. 2000, 7:77-85.
5. Ben-Shabat S., Kumar N., Domb A. PEG-PLA block-co-polymer as potential drug carrier: preparation and characterization. Macromol. Biosci. 2006, 6:1019-1025.
6. Berry M.R., Likar M.D. Statistical assessment of dissolution and drug release profile similarity using a model-dependent approach. J. Pharm. Biomed. Anal. 2007, 45:194-200.
7. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 1996, 9:512-531.
8. Brajtburg J., Powderly J.W.G., Kobayashi G.S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 1990, 34:183-188.
9. Chakrabarti A. Microbiology of systemic fungal infection. J. Postgrad. Med. 2005, 5:S16-S20.
10. Chernysheva Y.V., Babak V.G., Kildeeva N.R., Boury F., Benoit J.P., Ubrich N., Maincent P. Effect of the type of hydrophobic polymers on the size of nanoparticles obtained by emulsification-solvent evaporation. Mendeleev Commun. 2003, 13:65-67.
11. Choi K.C., Bang J.Y., Kim P.I., Kim C., Song C.E. Amphotericin B-incorporated polymeric micelles composed of poly(d,l-lactide-co-glycolide)/dextran graft copolymer. Int. J. Pharm. 2008, 355:224-230.
12. Chorny M., Fishbein I., Danenberg H.D., Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Control. Release 2002, 83:389-400.
13. Cohen B.E. Amphotericin B toxicity and lethality: a tale of two channels. Int. J. Pharm. 1998, 162:95-106.
14. Costa F.O., Sousa J.J., Pais A.A., Formosinho S.J. Comparison of dissolution profiles of Ibuprofen pellets. J. Control. Release 2003, 89:199-212.
15. Costa P., Sousa Lobo J.M. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13:123-133.
16. Dea-Ayuela M.A., Rama-Iniguez S., Sanchez-Brunete J.A., Torrado J.J., Alunda J.M., Bolas-Fernandez F. Anti-leishmanial activity of a new formulation of amphotericin B. Trop. Med. Int. Health 2004, 9:981-990.
17. Dong Y., Feng S.-S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25:2843-2849.
18. Ei-Arini S.K., Leuenberger H. Modelling of drug release from polymer matrices: effect of drug loading. Int. J. Pharm. 1995, 121:141-148.
19. Enoch D.A., Ludlam H.A., Brown N.M. Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol. 2006, 55:809-818.
20. Espada R., Valdespina S., Alfonso C., Rivas G., Ballesteros M.P., Torrado J.J. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int. J. Pharm. 2008, 361:64-69.
21. Ferdous A.J., Stembridge N.Y., Singh M. Role of monensin PLGA polymer nanoparticles and liposomes as potentiator of ricin A immunotoxins in vitro. J. Control. Release 1998, 50:71-78.
22. Gaumet M., Vargas A., Gurny R., Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 2008, 69:1-9.
23. Groneberg D.A., Giersig M., Welte T., Pison U. Nanoparticle-based diagnosis and therapy. Curr. Drug Targets 2006, 7:643-648.
24. Hartsel S., Bolard J. Amphotericin B: new life for an old drug. TiPS 1996, 17:445-449.
25. Hillery A.M. Supramolecular lipidic drug delivery systems: from laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv. Drug Deliv. Rev. 1997, 24:345-363.
26. 1HNMR spectroscopy. Biomaterials 1997, 18:27-30.
27. 3-PLA copolymer as polymersomes: preparation, characterization, and their evaluation as drug carrier. Biomacromolecules 2010, 11:1027-1035.
28. Jalil R., Nixon J.R. Microencapsulation using poly (l-lactic acid). II. Preparative variables affecting microcapsule properties. J. Microencapsul. 1990, 7:25-39.
29. Jullien S., Vertut-Croquin A., Brajtburg J., Bolard J. Circular dichroism for the determination of amphotericin B binding to liposomes. Anal. Biochem. 1988, 172:197-202.
30. Kwon H.-Y., Lee J.-Y., Choi S.-W., Jang Y., Kim J.-H. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids Surf., A: Physicochem. Eng. Asp. 2001, 182:123-130.
31. Lavasanifar A., Samuel J., Kwon G.S. The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-l-aspartamide). J. Control. Release 2002, 79:165-172.
32. Milhaud J., Ponsinet V., Takashi M., Michels B. Interactions of the drug amphotericin B with phospholipid membranes containing or not ergosterol: new insight into the role of ergosterol. Biochim. Biophys. Acta 2002, 1558:95-108.
33. Murakami H., Kawashima Y., Niwa T., Hino T., Takeuchi H., Kobayashi M. Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(-lactide-co-glycolide) nanoparticle. Int. J. Pharm. 1997, 149:43-49.
34. Ouellette M., Drummelsmith J., Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist. Update 2004, 257-266.
35. Prud'homme R.K., Norman L.R., Adamson D.H., Yildiz M.E., Robb I.D. Polymersome Compositions and Associated Methods of Use 2005, Princeton University, USA, Halliburton Energy Services, Inc., USA, 14 p.
36. Sangeetha S., Venkatesh D.N., Adhiyaman R., Santhi K., Suresh B. Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis. Trop. J. Pharm. Res. 2007, 6:653-659.
37. Scholes P.D., Coombes A.G.A., Illum L., Daviz S.S., Vert M., Davies M.C. The preparation of sub-200nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery. J. Control. Release 1993, 25:145-153.
38. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 2009, 86:215-223.
39. Sterling T.R., Merz W.G. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist. Update 1998, 1:161-165.
40. Tiyaboonchai W., Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int. J. Pharm. 2007, 329:142-149.
41. Tiyaboonchai W., Woiszwillo J., Middaugh C.R. Formulation and characterization of amphotericin B-polyethylenimine-dextran sulfate nanoparticles. J. Pharm. Sci. 2001, 90:902-914.
42. Vandermeulen G., Rouxhet L., Arien A., Brewster M.E., Preat V. Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(epsilon-caprolactone-co-trimethylenecarbonate) polymeric micelles. Int. J. Pharm. 2006, 309:234-240.
43. Vanneaux V., Proust V., Chéron M., Besnard M., Corriol O., Gimenez F., Singlas E., Legrand P. A physical and chemical stability study of amphotericin B lipid complexes (Abelcet) after dilution in dextrose 5%. Eur. J. Hosp. Pharm. 2007, 13:10-13.
44. Yildiz M.E., Prud'homme R.K., Robb I., Adamson D.H. Formation and characterization of polymersomes made by a solvent injection method. Polym. Adv. Technol. 2007, 18:427-432.
45. Yu B.G., Okano T., Kataoka K., Sardari S., Kwon G.S. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly([beta]-benzyl--aspartate) micelles. J. Control. Release 1998, 56:285-291.